Day By Day - Medtronic Plc (MDT) Analyse court terme - MEDTRONIC INC : La rÃ©sistance majeure est proche.

Report

Day By Day

Louis AZAIS

EUR 104.42 For Business Accounts Only

Analyse court terme - MEDTRONIC INC : La rÃ©sistance majeure est proche.

La tendance est toujours baissiÃ¨re, son niveau d'invalidation est au-dessus de 82,50 $. L'objectif est Ã 72,40 $.

Arguments :
- La rÃ©sistance majeure est proche.
- Les prix dÃ©passent la moyenne mobile, c'est un signal de force.

30/10/2017 1 FR

Underlying

Medtronic Plc

See profile

IE00BTN1Y115 New York Stock Exchange United States

Provider

Day By Day

DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.

See profile

Analysts

Louis AZAIS

Other Reports on these Companies

SmartInsider

Medtronic Plc: 1 director

A director at Medtronic Plc sold 8,605 shares at 91.580USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Free Trial

September 5, 2025 September 5, 2025 1 EN

ACF Equity Research

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurodegenerative diseases (NDDs); and a clinical-stage Dual Orexin Receptor Agonist (DOXA) platform targe...

May 29, 2025 May 29, 2025 1 EN

ACF Equity Research

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innovation 13032025

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecast over 35m US T1D + T2D sufferers. According to the CDC in 2021 there were 29.4m US diagnosed diabet...

March 13, 2025 March 13, 2025 1 EN

Short term view - GBP-CHF : The major resistance is close.

The trend remains neutral. Prices will have to break above the peak at CHF 1.3104 for the trend to be positive again with an invalidation level below CHF 1.2740.Arguments :- The major resistance is close.- The moving average is capping prices.

EUR 103.26

November 2, 2018 November 2, 2018 1 EN

Valérie GASTALDY

Valérie GASTALDY

La tendance est toujours neutre. Il faut franchir le sommet Ã 1,3104 CHF pour que la tendance devienne positive avec une invalidation sous 1,2740 CHF.Arguments :- La rÃ©sistance majeure est proche.- La moyenne mobile sert de rÃ©sistance.

EUR 103.26

November 2, 2018 November 2, 2018 1 FR

Valérie GASTALDY

Valérie GASTALDY

Short term view - GBP-USD : Pull-back

The trend is momentarily interrupted by a consolidation on a shorter time horizon but prices remain below the invalidation level at $1.3210. It can resume at anytime towards the target at $1.2600.Arguments :- Prices are pulling back to the major resistance level (previously a support). The fall will resume afterwards.- The falling moving average confirms our opinion.

EUR 103.26

November 2, 2018 November 2, 2018 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Analyse court terme - MEDTRONIC INC : La rÃ©sistance majeure est proche.

Medtronic Plc: 1 director

KDST + NLSP Combined Core Investment Case 29052025

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innovation 13032025

Short term view - GBP-CHF : The major resistance is close.

Analyse court terme - GBP-CHF : La rÃ©sistance majeure est proche.

Short term view - GBP-USD : Pull-back

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe